Trial Outcomes & Findings for Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion (NCT NCT02694198)

NCT ID: NCT02694198

Last Updated: 2016-05-16

Results Overview

mean cervicovaginal fetal fibronectin level in women undergoing midtrimesteric induction of abortion

Recruitment status

COMPLETED

Target enrollment

135 participants

Primary outcome timeframe

72 hours

Results posted on

2016-05-16

Participant Flow

Participant milestones

Participant milestones
Measure
Mid-trimester Abortion
The population of the study comprised 135 pregnant women attending Ain Shams University Maternity hospital at labor and delivery ward diagnosed with mid-trimester missed miscarriage confirmed by transabdominal ultrasound who will undergo termination by misoprostol
Overall Study
STARTED
135
Overall Study
COMPLETED
135
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Mid-trimester Abortion
n=135 Participants
The population of the study comprised 135 pregnant women attending Ain Shams University Maternity hospital at labor and delivery ward diagnosed with mid-trimester missed miscarriage confirmed by transabdominal ultrasound who will undergo termination by misoprostol
Age, Continuous
28.4 years
STANDARD_DEVIATION 4.02 • n=5 Participants
Sex: Female, Male
Female
135 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
Body mass index
29.4 kilograms per squared meter
STANDARD_DEVIATION 2.31 • n=5 Participants
gestational age in weeks
19.32 weeks
STANDARD_DEVIATION 1.91 • n=5 Participants
Outcome of induction of abortion
abortion in less than 24 hours
119 participants
n=5 Participants
Outcome of induction of abortion
abortion in more than 24 hours
13 participants
n=5 Participants
Outcome of induction of abortion
failed induction
3 participants
n=5 Participants

PRIMARY outcome

Timeframe: 72 hours

Population: Depending on Francesco et al., 2005 who found that Fetal fibronectin test positive in 19 among 270 (7.0%) women undergoing mid-trimester abortion. Assuming α=0.05 and confidence interval (CI)= 10.0% and by using PASS 11th release the minimal sample size is 120. With a possible 10% drop out of cases, the enrolled cases would be 135 cases.

mean cervicovaginal fetal fibronectin level in women undergoing midtrimesteric induction of abortion

Outcome measures

Outcome measures
Measure
Mid-trimester Abortion
n=135 Participants
The population of the study comprised 135 pregnant women attending Ain Shams University Maternity hospital at labor and delivery ward diagnosed with mid-trimester missed miscarriage confirmed by transabdominal ultrasound who will undergo termination by misoprostol
Cervicovaginal Fetal Fibronectin Level
39.4 nanogram per milliliter
Standard Deviation 7.9

PRIMARY outcome

Timeframe: 72 hours

Difference between women who expulsed the fetus within 24 hours and women who expulsed the fetus in more than 24 hours as regarding cervicovaginal fetal fibronectin level (ng/ml)

Outcome measures

Outcome measures
Measure
Mid-trimester Abortion
n=135 Participants
The population of the study comprised 135 pregnant women attending Ain Shams University Maternity hospital at labor and delivery ward diagnosed with mid-trimester missed miscarriage confirmed by transabdominal ultrasound who will undergo termination by misoprostol
Relation of Cervicovaginal Fetal Fibronectin Level to Duration of Induction of Abortion
women aborted within 24 hours n=129
39.3 nanogram per milliliter
Standard Deviation 7.71
Relation of Cervicovaginal Fetal Fibronectin Level to Duration of Induction of Abortion
women aborted in more than 24 hours or failed n=6
40.4 nanogram per milliliter
Standard Deviation 11.2

Adverse Events

Mid-trimester Abortion

Serious events: 0 serious events
Other events: 118 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Mid-trimester Abortion
n=135 participants at risk
The population of the study comprised 135 pregnant women attending Ain Shams University Maternity hospital at labor and delivery ward diagnosed with mid-trimester missed miscarriage confirmed by transabdominal ultrasound who will undergo termination by misoprostol
Surgical and medical procedures
Need for surgical removal of placenta
64.4%
87/135 • Number of events 87 • All participants were closely monitored during the process of induction of abortion and over the following 24 hours following spontaneous expulsion or surgical removal of the placenta.
General disorders
Shivering
3.7%
5/135 • Number of events 5 • All participants were closely monitored during the process of induction of abortion and over the following 24 hours following spontaneous expulsion or surgical removal of the placenta.
General disorders
Fever
4.4%
6/135 • Number of events 6 • All participants were closely monitored during the process of induction of abortion and over the following 24 hours following spontaneous expulsion or surgical removal of the placenta.
Gastrointestinal disorders
Nausea
8.9%
12/135 • Number of events 12 • All participants were closely monitored during the process of induction of abortion and over the following 24 hours following spontaneous expulsion or surgical removal of the placenta.
Gastrointestinal disorders
Diarrhea
2.2%
3/135 • Number of events 3 • All participants were closely monitored during the process of induction of abortion and over the following 24 hours following spontaneous expulsion or surgical removal of the placenta.
Gastrointestinal disorders
Vomiting
3.7%
5/135 • Number of events 5 • All participants were closely monitored during the process of induction of abortion and over the following 24 hours following spontaneous expulsion or surgical removal of the placenta.

Additional Information

amr ahmed mahmoud riad

Ain Shams Maternity hospital

Phone: 01005347179

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place